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In cooperative aggregation of bovine platelets induced by simultaneous addition of PAF and collagen at subthreshold concentrations the following 
observations were made. (i) Formation of phosphatidic acid and arachidonic acid metabolites, which characterize PAF and collagen alone-induced 
aggregation, respectively, was observed very obviously. (ii) A thromboxane antagonist did not completely block the cooperative aggregation. The 
extent of residual aggregation activity was dependent on concentration of collagen used in the simultaneous administration with PAF. These results 
suggest hat both signal transduction pathways activated by PAF and collagen alone at high concentrations are attained by simultaneous addition 
of both agonists at subthreshold concentrations through unknown mechanisms. 
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1. INTRODUCTION 
Various agonists induce aggregation of platelets 
through different mechanisms. Several papers reported 
that two different agonists demonstrate cooperativity 
in the aggregation [l-3]. However, mechanisms of 
this cooperativity have not been elucidated thoroughly. 
We previously found cooperativity between platelet- 
activating factor (PAF) and collagen using bovine 
platelets [4]. Cooperativity was observed at various 
steps of signal transduction pathway activated by PAF 
and collagen alone including changes of cytosolic Ca2 + 
concentration, thromboxane (TX) formation and 
phosphorylation of 47 kDa protein (manuscript in 
preparation). In bovine platelets, collagen-induced 
aggregation was fully dependent on endogenously 
formed TXA2, whereas PAF-induced one was not at 
all. 
We show here the results suggesting that collagen 
and PAF at subthreshold concentration enhanced one 
another’s activation pathway when they were added 
together. 
2. MATERIALS AND METHODS 
2.1. Materials 
PAF, collagen (type I), and TXBz were purchased from Avanti 
Polar Lipids (Pelham, AL), Hormon-Chemie GmbH. (Munich, 
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FRG) and Cayman Chemical (Ann Arbor, MI), respectively. 129 
Hydroxyeicosatetraenoic a id (12-HETE) was chemically synthesized 
[5]. ONO-3708 was kindly provided from Ono Pharmaceutical Co. 
(Osaka, Japan). All other reagents were of analytical grade. 
2.2. Preparation of bovine washed platelets 
Washed platelet suspension in Tris-acid citrate dextrose (ACD) 
buffer was prepared from bovine blood anticoagulated with ACD as 
described previously [6]. 
2.3. Measurement of platelet aggregation 
Platelet aggregation was mpnitored as increase of light transmis- 
sion in the presence of 8 mM CaCl2 and 1 mg/ml bovine serum 
albumin (essentially fatty acid free; Sigma) using a Nikoh Bioscience 
aggregometer NKK HEMA Tracer 601 (Tokyo, Japan). 
2.4. Measurement of phosphatidic acid (PA) and arachidonic acid 
metabolites 
Formation of PA and arachidonic acid metabolites was detected 
using [I-?]arachidonic acid (50 mCi/mmol, DuPont-New England 
Nuclear)-labeled platelets according to the method described 
previously [7]. Lipids were extracted from stimulated platelets and 
were separated by thin-layer chromatography (TCL) in the solvent 
system of benzene/dioxane/acetic a id (20:20: 1.5). Each %-labeled 
product was detected with Berthold Analytical Instruments radio 
TLC scanner model LB 284 (Nashua, NH) and was identified accord- 
ing to the Rr values of unlabeled authentic TXBz (Rr = 0.4) and 
12-HETE (Rf = 0.62), or the Rf value of [‘%Z]dipalmitoyl PA (Rr = 
0.2), which was made from cleavage of [r4C]dipalmitoyl 
phosphatidylcholine (DuPont-New England Nuclear) with 
phospholipase D (Boehringer Mannheim). 
3. RESULTS AND DISCUSSION 
As reported in a previous paper, cooperative ag- 
gregation showed aggregation patterns without lag time 
and disaggregation, which characterize the 
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simultaneous manifestation of both collagen and PAF 
alone-induced aggregation [4]. This unique aggregation 
pattern implicated that the aggregation was induced by 
stimulating both activation pathways of these agonists. 
This implication was corroborated in this study. 
Fig. 1 shows a thin-layer chromatogram of lipids 
derived from [‘4C]arachidonic acid-labeled platelets 
stimulated with PAF, collagen or their combination at 
subthreshold concentrations. Although 0.5 nM PAF or 
2 pg/ml collagen alone did not induce aggregation and 
formation of metabolites derived from 
[‘4C]arachidonic acid-labeled phospholipids (panel A), 
when added together, they induced extensive aggrega- 
tion and very obvious formation of both PA and 
arachidonic acid metabolites including TXBz and 
1ZHETE (panel B). With high concentration of PAF 
(4 nM) alone, very obvious aggregation was observed 
and only PA was formed and arachidonic acid 
metabolites were not formed at all (panel C). The situa- 
tion was completely opposite when high concentration 
of collagen (16 kg/ml) alone was used to aggregate 
platelets (panel D). Arachidonic acid metabolites were 
detected very distinctly, but PA was not detected at all. 
With this radioisotopic technique, radioactivity is 
preferentially incorporated in phosphatidylcholine [8], 
therefore, arachidonic acid metabolites we detected 
here should be derived mainly from phosphatidyl- 
choline probably by the activation of phospholipase 
AZ. Thus, we can say that PAF alone does not activate 
phospholipase AZ, but that PAF even at very low con- 
centration is able to support its activation by collagen 
at subthreshold concentration. This action of PAF 
might contribute to the cooperativity with collagen in 
aggregation. We could not explain why PA was not 
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Fig. 2. Effect of ONO-3708 on platelet aggregation. Washed bovine 
platelets were preincubated with various concentrations of 
ONO-3708 (1.5-12 PM) for 5 min at 37”C, followed by the addition 
of 1.6 nM PAF (a), 16 fig/ml collagen (f) or with simultaneous addi- 
tion of 0.4 nM PAF plus 6 pg/ml (a), 4 pg/ml (b), 2 @g/ml (c), 1 
pg/ml (d) and 0.5 pg/ml (e) collagen. Maximal aggregation activity 
within 7 min was plotted against concentration of ONO-3708 as 
relative to that obtained in the absence of it in each case. 
formed from 14C-labeled phospholipids in collagen- 
induced aggregation. It was reported that PA forma- 
tion was detectable along with collagen-induced ag- 
gregation of human and rat platelets using 32P as the 
probe, in which system combined action of 
phospholipase C and diacylglycerol kinase should be 
represented [9,10]. Indeed, we also obtained the same 
preliminary results using 32P-incubated bovine platelets 
(not shown). It is obvious that there are two different 
pathways for the formation of PA in bovine platelets, 
which can be detected by [‘4C]arachidonic acid-labeling 
and 32P-labeling techniques. One of them, formation 
from [‘4C]arachidonic acid-labeled phospholipids, is 
operative only with PAF. It becomes of interest o note 
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Fig. 1. Radio TLC profiles of lipids produced by platelets (2.5 x lo8 platelets1500 ~1) stimulated by following agonists. (A) 0.5 nM PAF or 2 
cg/ml collagen alone for 7 min. (B) 0.5 nM PAF + 2 pg/ml collagen for 7 min. (C) 1.6 nM PAF alone for 4 min. (D) 16 @g/ml collagen alone 
for 7 min. 
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that both activation pathways of two agonists, namely 
the formation of [r4C]PA and arachidonic acid 
metabolites, function very actively when PAF and col- 
lagen are added simultaneously at subthreshold concen- 
trations. 
Fig. 2 shows the effect of a TXA2 antagonist, 
ONO-3708 [ Ill, on platelet aggregation. Aggregation 
induced by high concentration of collagen (16 pg/ml) 
alone was almost completely inhibited at 1.5 PM 
ONO-3708 (curve f), whereas high concentration of 
PAF (1.6 nM) alone-induced aggregation was not af- 
fected even at 12 PM (line a). In the case of cooperative 
aggregations induced by simultaneous addition of PAF 
at subthreshold concentration (0.4 nM) and collagen at 
various concentrations (0.5-6 pg/ml), the effect of an- 
tagonist was in-between these two extreme cases. The 
lower the concentration of collagen, the higher was the 
effect of the antagonist. In combination of 6 pg/ml col- 
lagen and 0.4 nM PAF, the effect of ONO-3708 was nil 
as was observed with PAF alone (line a). The same kind 
of results were obtained with aspirin (not shown). Col- 
lagen and PAF alone used in cooperative aggregation 
could not induce aggregation at all under our ex- 
perimental conditions. This result suggests that 
cooperative aggregation was induced by combination 
of two activation pathways, one dependent on TXA2 
and the other independent. Detailed mechanisms of this 
interesting cooperativity between PAF and collagen re- 
main to be elucidated. 
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